REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) Director Kenneth T. Mills sold 20,602 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the sale, the director now owns 475,103 shares in the company, valued at $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

REGENXBIO Stock Up 3.7%

RGNX opened at $8.64 on Friday. The business has a fifty day moving average of $7.48 and a 200 day moving average of $7.98. The stock has a market cap of $433.01 million, a P/E ratio of -1.72 and a beta of 1.11. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $16.26.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). The company had revenue of $89.01 million for the quarter, compared to analysts’ expectations of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. Equities analysts anticipate that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. GAMMA Investing LLC increased its position in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the period. FNY Investment Advisers LLC purchased a new position in REGENXBIO during the 1st quarter worth $35,000. Brooklyn Investment Group raised its position in REGENXBIO by 163.7% during the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in REGENXBIO during the 4th quarter valued at $54,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of REGENXBIO in the 4th quarter worth $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on RGNX. Raymond James initiated coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective on the stock. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. Finally, The Goldman Sachs Group reduced their target price on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus price target of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.